After Market

In this episode, OTC Markets Group executive vice president Jason Paltrowitz joins Proactive to discuss how international companies—especially those listed on the Australian Securities Exchange (ASX)—can efficiently expand their reach to United States investors through secondary trading on OTC Markets. Paltrowitz explains the challenges U.S. investors face when trying to access equities listed on overseas exchanges such as the ASX, London Stock Exchange, or Euronext Paris. He outlines how OTC Markets bridges this gap by allowing these companies to make their shares available in U.S. dollars during U.S. trading hours, through regulated trading platforms. The episode also explores OTC Markets’ three-tiered structure, with a focus on OTCQX—the “best market”—and OTCQB, the “venture market,” tailored for growth-stage companies. Over 80 ASX-listed companies are already leveraging these platforms. Paltrowitz introduces the “List Local, Trade Global” strategy, enabling firms to maintain their primary listings at home while gaining exposure to U.S. liquidity—without the added burden of full U.S. regulatory compliance such as SEC filing or Sarbanes-Oxley. The conversation concludes with a look at rising U.S. investor interest in international equities—Asian and European trading volumes have surged—and previews upcoming innovations like overnight trading and the OTCID platform aimed at enhancing market access and transparency.

Race Oncology Ltd is advancing the development of a reformulated chemotherapy drug aimed at reducing severe side effects, particularly cardiac-related risks, while preserving or improving efficacy. In this episode of After Market with Jonathan Jackson, CEO and managing director Daniel Tillett highlighted the drug’s potential to work alongside anthracyclines, a common class of chemotherapy agents, to enhance patient safety and treatment outcomes. The company is preparing for clinical trials to evaluate the drug’s performance in human subjects.

Amplia Therapeutics Ltd CEO and managing director Dr Chris Burns has had a long career in drug development, including discovering only the second Australian drug to receive US FDA approval. He has plenty of advice to share for Australian-based researchers and domestically developed biotech assets. Proactive's Susanna Nelson chats to him about the current state of clinical research and commercial drug development in Australia.

Australian Vanadium Ltd (ASX:AVL) CEO Graham Arvidson sits down with Proactive’s Jonathan Jackson to discuss progress in the company's metallurgical testing following a recent merger with Technology Metals Australia Ltd (TMT). AVL plans to capitalise on the battery metal boom with its vanadium and high-grade iron project, leveraging its subsidiary VSUN to build out the Vanadium Flow Battery market and other future tech applications.

How can resource companies mitigate their carbon emissions in innovative ways? Proactive’s Phoebe Shields talks to CSIRO’s Dr Dia Milani, who leads the organisation’s CO2 utilisation team within the Sustainable Carbon Technologies group, about the urgency of including carbon capture and storage methods in the mix of tools to combat climate change – and the opportunities that abound for companies to apply the technology in Australia.

Artemis Resources Ltd executive director George Ventouras talks to Proactive’s Susanna Nelson about the company’s projects, mostly in the West Pilbara, where it is exploring for gold, copper and lithium. George also weighs in on ‘the white gold boom’, the importance of a diverse and sustainable mining industry to the Australian economy and the future of mining in this country.

China is our biggest trading partner. In this introduction to the topic, mining publisher and China entrepreneur Yolanda Torrisi tells Proactive about the Australian industries that are most exposed to the trading giant, whether diplomatic relations are starting to defrost, and how we can leverage the relationship to our best advantage at a time of uncertainty for global markets and supply chains.

Energy security is critical in these days of geopolitical unrest. Provaris Energy Ltd has seen the writing on the wall and has forged ahead with its business model of simple and efficient hydrogen production and transportation. MD and CEO Martin Carolan tells Proactive's Susanna Nelson the company is currently in the design phase of a prototype tank for compressed hydrogen, with construction and testing planned in Norway for the first quarter of 2024. A range of government and independent stakeholders are interested, too.

Clinical trials are, by necessity, subject to rigorous guidelines to protect human health. Proactive’s Phoebe Shields talks to Evrima founder and CEO Charlotte Bradshaw about her company’s data-driven patient matching system, which verifies and matches participants’ electronic medical records to trial protocols. This breaks down barriers to trial recruitment such as awareness, hospital-centricity, distribution of patients, commitment to participation and suitability to take part.

Clinical-stage immuno-oncology biotech Imugene has been making significant strides in the development of therapies targeting a range of cancers. In this episode of After Market, MD and CEO Leslie Chong tells Susanna Nelson about the company's Phase 1 metastatic advanced solid tumours, or MAST, trial, which has been designed to evaluate the safety and efficacy of the cancer-killing virus CF33-hNIS (VAXINIA).

The last few years have seen investors buffeted by the winds of pandemic and war, bringing with them supply chain issues, overcooked inflation and much-dreaded rate hikes. Atrium senior portfolio manager Brendan Paul talks to Proactive about why it’s an interesting time to be an investor, what risk really means and the importance of building a truly diverse asset portfolio in uncertain times.

Antimicrobial resistance means the age of antibiotics – when humanity has had the luxury of fixing or preventing all manner of disease with a simple biological agent in a capsule – is coming to an end. Recce Pharmaceuticals CEO James Graham talks to Proactive’s Susanna Nelson about how we stay one step ahead in the fight against deadly pathogens and avoid the next superbug.

The critical mineral boom is taking off. CSIRO senior principal research scientist and Green Mineral Technologies initiative leader Chris Vernon walks Proactive’s Phoebe Shields through the oncoming critical mineral supply dearth, the need for down-stream trade relationships and the potential effect of a circular economy on the mining industry.

What are the rules governing cannabis and psychedelics in Australia? How have attitudes to these substances changed over time, and what does the Australian biotech industry need governments to do to unlock the myriad therapeutic benefits they promise? Emyria's Dr Michael Winlo answers these questions and more in this interview with Proactive's Susanna Nelson.

With AI all over news, it’s hard to sort out the opportunity from the threat. Avanade’s Warwick Talbot tells Proactive’s Phoebe Shields about the business potential presented by digitisation, machine learning’s use in data curation and real time insights, and the emergence of the industrial metaverse and digital twinning.

Long-time indigenous policy maker and advocate Ian Hamm chats to Proactive’s Susanna Nelson about the complex interplay between mining and Aboriginal rights over time. Ian argues for a seat at the board table for Aboriginal and Torres Strait Islander Peoples and expresses his hope that the looming referendum on the Voice to Parliament will usher in a period of genuine change.

Australian Electric Vehicle Association president Dr Chris Jones discusses the past, present and future of electric vehicles with Proactive’s Phoebe Shields, with insights from his own career in academia and as a change maker. What will be needed to bring about a change in attitudes toward the transportation of the future in Australia, and how do we achieve it?

Riversgold Ltd CEO Julian Ford talks to Proactive’s Phoebe Shields about the importance of the current battery minerals rush, and describes his journey from Apartheid South Africa to Australia and how it shaped his attitude to work, life and mining. A troubleshooter by nature, Ford looks for solutions, and there is none more pressing than the need to ramp up critical minerals production at a time of global decarbonisation.

Lightning Minerals CEO Alex Biggs tells Proactive’s Phoebe Shields about his eventful early life, personal hardship and eventual foray into critical minerals mining. Alex explains how his background has informed his personal philosophy and why resilience, integrity and a commitment to the social contract is key to his understanding of why he does what he does.

Welcome to After Market, the podcast from Proactive Australia with its finger firmly on the investor pulse. Each month we take a closer look at the issues shaping and shifting the markets - from cost of living to climate, geopolitics to geology, macroeconomics to medtech and big data to battery metals. Please note that the views of our interviewees are not the views of Proactive Investors. Seek independent investment advice before making any financial decisions and remember that nothing you hear on this pod constitutes investment advice.